Second-round tests begin on StrataGraft burn treatment developed in Madison
166020
post-template-default,single,single-post,postid-166020,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

Second-round tests begin on StrataGraft burn treatment developed in Madison

Second-round tests begin on StrataGraft burn treatment developed in Madison

By Judy Newman, Wisconsin State Journal

StrataGraft is human cell-based skin tissue to treat burn woundsA second round of studies has begun on a skin tissue product developed by a Madison company, designed to treat patients with serious burns.

The first patient has been enrolled in a Phase 2 study of StrataGraft, the skin tissue developed by Madison-based Stratatech, now part of Mallinckrodt, a global pharmaceutical company.

 The study is expected to follow 20 patients to evaluate the success of StrataGraft in healing their wounds over a three-month period. The study is expected to be completed by late 2018, Mallinckrodt said. Read more …